1.
Lung Cancer
; 120: 60-61, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29748016
RESUMO
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.